BI 224436: Difference between revisions
Appearance
Content deleted Content added
added Category:Experimental drugs using HotCat |
fixed structure and chem identifiers, removed image with incorrect structure |
||
Line 1: | Line 1: | ||
{{Drugbox |
{{Drugbox |
||
| IUPAC_name = ( |
| IUPAC_name = (2S)-[4-(2,3-Dihydropyrano[4,3,2-de]quinolin-7-yl)-2-methyl-3-quinolinyl][(2-methyl-2-propanyl)oxy]acetic acid |
||
| image = |
| image = |
||
<!--Identifiers--> |
<!--Identifiers--> |
||
| CAS_number = |
| CAS_number = 1155419-89-8 |
||
| PubChem = |
| PubChem = 66561902 |
||
| DrugBank = |
| DrugBank = |
||
| ChemSpiderID = |
| ChemSpiderID = 32698770 |
||
| UNII = 99A996378Y |
|||
| ATCvet = |
| ATCvet = |
||
| ATC_prefix = none |
| ATC_prefix = none |
||
Line 13: | Line 14: | ||
<!--Chemical data--> |
<!--Chemical data--> |
||
| C=24 | H=25 | N=1 | O=4 |
| C=24 | H=25 | N=1 | O=4 |
||
| molecular_weight = |
| molecular_weight = 442.515 g/mol |
||
| smiles = CC( |
| smiles = CC1=NC2=CC=CC=C2C(=C1[C@@H](C(=O)O)OC(C)(C)C)C3=C4C5=C(C=C3)OCCC5=CC=N4 |
||
| StdInChI = 1S/ |
| StdInChI = 1S/C27H26N2O4/c1-15-21(25(26(30)31)33-27(2,3)4)23(17-7-5-6-8-19(17)29-15)18-9-10-20-22-16(12-14-32-20)11-13-28-24(18)22/h5-11,13,25H,12,14H2,1-4H3,(H,30,31)/t25-/m0/s1 |
||
| StdInChIKey = |
| StdInChIKey = MIXIIJCBELCMCZ-VWLOTQADSA-N |
||
<!--Clinical data--> |
<!--Clinical data--> |
Revision as of 21:09, 30 August 2017
Clinical data | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 7 hrs (simulated)[1] |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C24H25NO4 |
Molar mass | 442.515 g/mol g·mol−1 |
3D model (JSmol) | |
| |
|
BI 224436 is an investigational new drug under development for the treatment of HIV infection. BI 224436 is the first non-catalytic site integrase inhibitor (NCINI). It inhibits HIV replication via binding to a conserved allosteric pocket of the HIV integrase enzyme. This makes the drug distinct in mechanism of action compared to raltegravir and elvitegravir, which bind at the catalytic site.[2] In October 2011, Gilead Sciences purchased exclusive rights to develop BI 224436 and several related compounds under investigation in Boehringer Ingelheim’s noncatalytic site integrase inhibitor program.[3][4]
References
- ^ Pharmacodynamics of BI 224436 for HIV-1 in an in vitro hollow fiber infection model system
- ^ Levin, Jules. BI 224436, a Non-Catalytic Site Integrase Inhibitor, is a potent inhibitor of the replication of treatment-naïve and raltegravir-resistant clinical isolates of HIV-1. Conference Reports for NATAP. ICAAC Chicago Sept 17-20 2011.
- ^ Gilead Negotiates Worldwide License to BI’s Early Clinical Stage HIV Program. Genetic Engineering and Biotechnology News. 6 Oct 2011.
- ^ Highleyman, Liz. ICAAC: New Integrase Inhibitor BI 224436 Active against Raltegravir-Resistant HIV. HIVandHepatitis.com. 7 Oct 2011.